This observed discrepancy of GAS5 clinical value for NMIBC and MIBC patients could possibly be attributed to the well-documented diversity of non-muscle-invasive (superficial) and muscle-invasive tumours, regarding cellular origin and molecular background,37–40 and clearly highlights the NMIBC-specific prognostic utility of GAS5. Here, GAS5 is linked to neoplasm.